Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with autoimmune disease: A phase 2, randomized, double-blind, placebo-controlled clinical trial
Clinical Infectious Diseases Sep 20, 2017
Eberhardson M, et al. - In this work, an evaluation of immunogenicity and safety of inactivated zoster vaccine (ZVIN) was performed in adults with autoimmune disease. As per observations, ZVIN was well tolerated and elicited statistically significant varicella-zoster virus (VZV)-specific immune responses in these patients approximately 28 days post-dose 4, measured by gpELISA and IFN-γ ELISPOT.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
